<DOC>
	<DOCNO>NCT01256164</DOCNO>
	<brief_summary>The purpose study characterize safety hemostatic activity topical Fibrocaps surgical patient control mild moderate bleed standard surgical technique ineffective and/or impractical .</brief_summary>
	<brief_title>U.S. Study Fibrocaps Surgical Hemostasis</brief_title>
	<detailed_description>This multi-center , prospective , randomize , single-blind , control , comparative efficacy safety trial 90 subject undergoing spinal surgery , hepatic resection , specific soft tissue dissection , peripheral vascular surgery , ( ( include peripheral artery bypass arteriovenous graft formation hemodialysis use either Polytetrafluoroethylene ( PTFE ) native graft ) ) . Subjects randomized 2:1 ratio Fibrocaps + Gelfoam Gelfoam day surgery . Use Fibrospray device optional spinal vascular surgery , require general surgery procedure . All investigator use Fibrospray device train correct safe set-up use Fibrocaps Fibrospray device prior participate clinical trial .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<mesh_term>Gelatin Sponge , Absorbable</mesh_term>
	<criteria>male female 18 year age old Subjects able willing provide write sign informed consent All subject willing use medically accept form contraception time consent completion followup study visit A life expectancy least one year IntraOperative inclusion criterion Presence mild moderate bleeding/oozing control conventional surgical technique , include limited suture , ligature cautery ineffective impractical Absence intraoperative complication bleed , opinion investigator , may interfere assessment efficacy safety No intraoperative use topical hemostat contain thrombin Approximate Target Bleeding Site surface area 100 square centimeter Pregnant lactate woman Has know intolerance blood product Fibrocaps component Unwilling receive human blood product Subject know allergy porcine gelatin Has mental physical condition would , opinion investigator , place subject unacceptable risk render subject unable meet requirement protocol Currently participate participate another clinical study involve another investigational agent within 4 week start trial , plan participation another clinical trial 4 week surgery Has clinicallysignificant coagulation disorder may interfere assessment efficacy pose safety risk subject accord investigator Aspartate Aminotransferase ( AST ) Alanine aminotransferase ( ALT ) 3 time ( ) upper limit normal range screening , except subject undergo liver resection surgery upper limit analytes due nature disease . Platelets &lt; 10 x 10^9 /L screen Activated partial thromboplastin time ( aPTT ) &gt; 100 second screen International normalized ratio ( INR ) great 2.5 screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>fibrin sealant</keyword>
	<keyword>hemostatics</keyword>
	<keyword>time hemostasis</keyword>
</DOC>